Publications by authors named "Magnus Polla"

Claim this Profile
P
Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.
Weier Qi, Simina M Boca, Alessandro Boianelli, Monica Fredberg, Sara Lundqvist, Magnus Polla

J Pharmacol Exp Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway.
Richard J Mills, Benjamin L Parker, Gregory A Quaife-Ryan, Holly K Voges, Elise J Needham, Magnus Polla

Cell Stem Cell· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward Second-Generation Cardiomyogenic and Anti-cardiofibrotic 1,4-Dihydropyridine-Class TGFβ Inhibitors.
Daniel Längle, Tessa R Werner, Fabian Wesseler, Elena Reckzeh, Niklas Schaumann, Magnus Polla

ChemMedChem· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1.
Linda Sundström, Susanna Myhre, Monika Sundqvist, Andrea Ahnmark, William McCoull, Magnus Polla

PLoS One· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low Bioavailability.
Vincent Andersson, Fredrik Bergström, Jonas Brånalt, Gunnar Grönberg, David Gustafsson, Magnus Polla

J Med Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa).
Mikael Brink, Anders Dahlén, Thomas Olsson, Magnus Polla, Tor Svensson

Bioorg Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Composite multi-parameter ranking of real and virtual compounds for design of MC4R agonists: renaissance of the Free-Wilson methodology.
Ingemar Nilsson, Magnus O Polla

J Comput Aided Mol Des· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development.
Johan L Willemse, Magnus Polla, Thomas Olsson, Dirk F Hendriks

Clin Chim Acta· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays.
Johan L Willemse, Magnus Polla, Dirk F Hendriks

Anal Biochem· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa).
Magnus O Polla, Louise Tottie, Carita Nordén, Marcel Linschoten, Djordje Müsil

Bioorg Med Chem· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis